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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.023Type 2 diabetes mellitus is characterized by dyslipidemia with elevated free fatty acids (FFAs). Loss of
podocytes is a hallmark of diabetic nephropathy, and podocytes are highly susceptible to saturated FFAs
but not to protective, monounsaturated FFAs. We report that patients with diabetic nephropathy
develop alterations in glomerular gene expression of enzymes involved in fatty acid metabolism,
including induction of stearoyl-CoA desaturase (SCD)-1, which converts saturated to monounsaturated
FFAs. By IHC of human renal biopsy specimens, glomerular SCD-1 induction was observed in podocytes
of patients with diabetic nephropathy. Functionally, the liver X receptor agonists TO901317 and
GW3965, two known inducers of SCD, increased Scd-1 and Scd-2 expression in cultured podocytes and
reduced palmitic acideinduced cell death. Similarly, overexpression of Scd-1 attenuated palmitic acide
induced cell death. The protective effect of TO901317 was associated with a reduction of endoplasmic
reticulum stress. It was lost after gene silencing of Scd-1/-2, thereby conﬁrming that the protective
effect of TO901317 is mediated by Scd-1/-2. TO901317 also shifted palmitic acidederived FFAs into
biologically inactive triglycerides. In summary, SCD-1 up-regulation in diabetic nephropathy may be
part of a protective mechanism against saturated FFA-derived toxic metabolites that drive endoplasmic
reticulum stress and podocyte death. (Am J Pathol 2013, 183: 735e744; http://dx.doi.org/10.1016/
j.ajpath.2013.05.023)Supported by Swiss National Science Foundation grants 31003A-119974
and 31003A-144112/1 (A.W.J.), Novartis Foundation for Medical Bio-
logical Research 10C57 (A.W.J.), Swiss National Science Foundation
Fellowship PBBSP3-144160 (J.S.), and National Institutes Health Grants
DK62472 and DK57683 (P.M.), NIH/N IDDK K08 DK0933783-01
(A.W.), and the Else-Kröner-Fresenius Foundation (C.D.C.).Diabetic nephropathy (DN) is the major cause of end-stage
renal disease, and most affected patients have type 2 dia-
betes.1,2 Podocyte injury and loss are critical events in DN3
and precede albuminuria.4e6 Type 2 diabetes mellitus is
characterized by hyperglycemia and dyslipidemia with
increased plasma levels of free fatty acids (FFAs).7 Intra-
glomerular lipid deposits in the kidneys of diabetic humans
were described in 1936 by Kimmelstiel and Wilson.8
However, the potential role of FFAs and fatty acid meta-
bolism in the pathogenesis of DN is only emerging.
Recently, we reported that podocytes are highly suscep-
tible to the saturated FFA palmitic acid, which induces
podocyte death.9 Mechanistically, palmitic acideinduced
podocyte death is linked to endoplasmic reticulum (ER)
stress that involves the proapoptotic transcription factorstigative Pathology.
.C/EBP homologous protein (CHOP).9 In contrast, mono-
unsaturated FFAs (MUFAs), such as palmitoleic or oleic acid,
attenuate palmitic acideinduced lipotoxicity in podocytes.9
The cytoprotective actions of MUFAs are incompletely
understood. Several studies indicated that MUFAs can induce
fatty acid oxidation and increase lipid storage in the form of
triglycerides (TGs), thereby reducing cytotoxic metabolites,
such as diacylglycerides (DAGs).10 Essential enzymes in the
synthesis of TGs are acyl-CoA:diacylglycerolacyltransferases
Sieber et al(DGATs), which transfer acyl-CoAs to DAGs,11,12 and
stearoyl-CoA desaturases (SCDs), which desaturate saturated
FFAs and thereby provide DGATs with their preferential
substrates, MUFAs.13,14 Four SCD isoforms have been iden-
tiﬁed in mice.15e17 Scd-1 and Scd-2 are ubiquitously
expressed, whereas Scd-3 is restricted to preputial glands,
harderian glands, and the skin. Scd-4 is thought to be solely
expressed in the heart.17,18 The predominant isoform in the
kidney is Scd-1.18 Scd-1 is positively regulated by liver X
receptor (LXR)19 and by LXR-mediated stearoyl regulatory-
element binding protein 1c.20 In humans, two SCD iso-
forms, SCD-1 and SCD-5, are known, of which only SCD-1
has high homology with the murine isoforms.21
We describe changes in the gene expression of key
enzymes of fatty acid metabolism in glomeruli of patients
with DN. Up-regulation of SCD-1 mRNA expression was
the predominant change, which correlated with up-
regulation of Scd-1 protein abundance in podocytes in
kidney biopsy specimens from patients with type 2 DN.
Functionally, Scd-1 can protect against palmitic acide
induced podocyte death, suggesting that SCD-1 up-regulation
in DN is a protective response of podocytes to the diabetic
milieu.
Experimental Design and Methods
Patients and Microarray Analysis
For microarray analysis, samples from the European Renal
cDNA Bank-Kröner-Fresenius Biopsy Bank were used.22
Total RNA was isolated from microdissected glomeruli,
reverse transcribed, and ampliﬁed as reported.23 Affymetrix
Expression Analysis Technical Manual (Affymetrix, Santa
Clara, CA) was used. ChipInspector version 2.1 (Genomatix
Software GmbH, Munich, Germany) was used for transcript
annotation, total intensity normalization, signiﬁcance anal-
ysis of microarrays, and transcript identiﬁcation based on
signiﬁcantly changed probes.24 No fold change cut-off was
applied, but minimum coverage of probes with signiﬁcant
alteration per transcripts was set at ﬁve.
Renal Histology
Parafﬁn-embedded normal kidney sections from tumor
nephrectomy specimens and renal biopsy specimens were
obtained from the Renal Pathology Service at Brigham and
Women’s Hospital (Boston, MA; institutional review board
protocol 2011-P-002692/3). Sections (4 mm) were deparafﬁ-
nized and rehydrated. Endogenous peroxidase activity was
quenched, and antigen retrieval was performed. The sections
were incubated with antieSCD-1 (sc-14719; 1:100, Santa
Cruz, Dallas, TX) for 40 minutes at room temperature.
Application of the secondary antibodies was followed by
incubation with biotinylated rabbit anti-goat at 1:200 dilution
(Vector Laboratory,Burlingame,CA). Sections incubatedwith
ABC reagent were visualized with 3,30-diaminobenzidine plus736substrate-chromogen followed by counterstaining with gill
hematoxylin. Imageswere taken in amaskedmanner by a renal
pathologist (A.W.).
Compounds, Cell Culture, Fatty Acid Preparation, and
Cell Death Analysis
TO901317 and GW3965 were obtained from Sigma (Buchs,
Switzerland). Podocytes were cultured as described pre-
viously.9 FFAs were prepared as previously described.9
Annexin V and PI staining was performed as reported.9
Annexin Vepositive/propidium iodideenegative podocytes
were considered apoptotic, whereas annexin Vepositive/
propidium iodideepositive podocytes were considered (late
apoptotic) necrotic cells.
Vectors and Lentivirus Production
For gene silencing, Scd-1 (50-GCCTTTAATCAACCCAA-
GAAA-30) and Scd-2 (50-GAACATTAGCTCTCGGGA-
GAA-30) shRNAs in a PLKO.1 puro vector were obtained
from Sigma. A 21-nt scrambled sequence (50-GACCGC-
GACTCGCCGTCTGCG-30 or 50-GAACATTAGCTCTC-
GGGAGAA-30) served as a control. For overexpression
studies, murine Scd-1 cDNA under a cytomegalovirus
promoter in an EZ-Lv153 vector was from GeneCopoeia
(Rockville, MD). Green ﬂuorescent protein in a pLVX-puro
vector, served as a control. Lentivirus production and podo-
cyte transduction were performed as previously reported.9
Western Blot
Western blotting was performed as previously described.9
Antibodies against SCD-1 and cleaved caspase 3 (Nos.
2794 and 9661; Cell Signaling Technology, Danvers, MA),
CHOP (sc-7351; Santa Cruz), GAPDH (EMD Millipore,
Billerica, MA), and b-actin (Sigma) were applied at dilu-
tions of 1:100, 1:1000, 1:5000, and 1:100,000, respectively.
Quantitative Real-Time PCR
Total RNA extraction, cDNA synthesis, and real-time PCR
were performed as previously reported.9 Primer sequences:
AccI forward 50-GCCTCTTCCTGACAAACGAG-30, re-
verse 50-TGACTGCCGAAACATCTCTG-30, AccII forward
50-ACAGAGATTTCACCGTCGCGT-30, reverse 50-CGC-
AGCGATGCCATTGT-30,25 Cpt-1a forward 50-CGCACG-
GAAGGAAAATGG-30, reverse 50-TGTGCCCAATATTC-
CTGG26-30, Cpt-1b forward 50-CAAGTTCAGAGACGA-
ACGCC-30, reverse 50-TCAAGAGCTGTTCTCCGAAC-
TG-30,26 Cpt-1c forward 50-AGAAGTAGAGCTCAGCTC-
GCCA-30, reverse 50-CCAGAGATGCCTTTTCCAGGAG-
30,27 Dgat1 forward 50-GTGCACAAGTGGTGCATCAG-30,
reverse 50-CAGTGGGACCTGAGCCATC-30,28 Dgat2 for-
ward 50-AGTGGCAATGCTATCATCATCGT-30, reverse
50-AAGGAATAAGTGGGAACCAGATCA-3029), Gapdhajp.amjpathol.org - The American Journal of Pathology
SCD-1 and -2 Protect Podocytesforward 50-CTGCACCACCAACTGCTTAGC-30, reverse
50-GGCATGGACTGTGGTCATGAG-30, Lxra forward 50-
CGACAGAGCTTCGTCCACAA-30, reverse 50-GCTCGT-
TCCCCAGCATTTT-30,30 Lxrb forward 50-AAGCAGGT-
GCCAGGGTTCTT-30, reverse 50-TCAATGGTGGACGC-
CTTCA-30,30 Scd-1 forward 50-TCTTGTCCCTATAGCC-
CAATCCAG-30, reverse 50-AGCTCAGAGCGCGTGTTC-
AA-3031 and Scd-2 forward 50-AGTGTTGCTCGTGAG-
CCTGTG-30, reverse 50-CCTGCAGATCCATGTCCAGC-
TA-30.31
Incorporation of Palmitic Acid into DAGs and TGs and
b-Oxidation
Pretreatment with TO901317 was performed for 14 hours.
The experiment was performed in serum-free medium sup-
plemented with 0.5% FFA-free bovine serum albumin (BSA)
containing 200 mmol/L palmitic acid or palmitic plus oleic
acid (100 mmol/L each) in the presence of 0.5mCi/mL of [3H]-
palmitic acid (PerkinElmer, Schwerzenbach, Switzerland). 32
For DAG and TG analysis, cells werewashed three timeswith
PBS and scraped in PBS. Lipidswere extracted in chloroform/
methanol/5N HCl (2:1:0.05, v/v). The organic phase was
dried under N2 and redissolved in chloroform. Lipids were
separated by unidimensional thin layer chromatography on
20  20-cm silica plates (Sigma, Buchs, Switzerland) in n-
hexane/diethyl ether/methanol (45:10:1, v/v). Lipid standards
(glyceryl tripalmitate, glyceryl trioleate, and 1,2 dipalmitoyl-
sn-glycerol from Sigma) were visualized by spraying with
KMnO4 stain. The spots corresponding to markers were
scraped, and after addition of 150 mL ofmethanol and 2mL of
scintillation buffer radioactivity was measured. DAGs and
TGs were normalized to total lipid. For b-oxidation, 1 mL of
culture medium was transferred to 5 mL of chloroform/
methanol/5N HCl (2:1:0.05, v/v). Aqueous phase (500 mL;
containing 3H2O) was added to 2 mL of scintillation buffer
before measuring radioactivity.
Statistical Analysis
Data are expressed as means  SD. Signiﬁcance of differ-
ences was calculated with a two-sided, unpaired t-test. The
description of the signiﬁcance analysis of microarray data is
given in Patients and Microarray Analysis.
Results
Differential Regulation of Genes Involved in Fatty Acid
Metabolism in Glomeruli of Patients with Established
DN
Microarray analysis of enzymes involved in fatty acid
metabolism in glomeruli of patients with type 2 diabetes
mellitus compared with pretransplantation living donors
revealed signiﬁcantly altered expression levels of enzymes
involved in fatty acid oxidation and TG synthesis (Figure 1A;The American Journal of Pathology - ajp.amjpathol.orgfor patient characteristics see Supplemental Table S1). First,
the up-regulation of all three isoforms of carnitine palmi-
toyltransferase (CPT)-1, the rate-limiting enzyme for fatty
acid oxidation, and the down-regulation of acetyl-CoA
carboxylase (ACC)-2, which catalyzes the formation of the
CPT-1 inhibitor malonyl-CoA, was observed, suggesting
disposition for increased fatty acid oxidation (Figure 1A).
Second, the prominent induction of SCD-1, which provides
DGATs with their preferential substrates, MUFAs, together
with the positive regulation of DGAT1, which catalyzes the
incorporation of exogenous FFAs into TG, implies a dispo-
sition toward increased TG synthesis (Figure 1A).
To localize expression of SCD-1 in human glomeruli and
to investigate whether glomerular up-regulation of SCD-1
mRNA in DN is also reﬂected on the protein level, renal
biopsy specimens were stained for SCD-1. Normal glomeruli
from tumor nephrectomy specimens revealed minimal
glomerular staining for SCD-1 (Figure 1B). In contrast, in
biopsy specimens from type 2 diabetic patients with DN
a clear signal for SCD-1 could be observed in glomeruli,
predominately in podocytes (Figure 1D).
Palmitic Acid Induces Scd-1, Scd-2, and Cpt-1a in
Podocytes
To address the potential contributory role of FFAs to the
altered gene expression proﬁle in glomeruli and podocytes of
patients with DN, we treated cultured podocytes with palmitic
acid as previously reported.9 Exposure for 14 hours to 200
mmol/L palmitic acid complexed to BSA, compared with
uncomplexed BSA, increased Scd-1 (1.7-  0.7-fold, P <
0.01) (Figure 1C) and Scd-2 (1.9-  0.6-fold, P < 0.001)
(Figure 1C), the most abundant SCD isoforms in murine
kidneys18 (Supplemental Figure S1A) and murine podocytes
(Supplemental Figure S1B). Also, Cpt-1a was signiﬁcantly
increased (2.9-  0.9-fold, P < 0.0001) (Figure 1C). No
differences were found for Cpt-1b, Cpt1c, AccI, AccII, and
Dgat1, which could be due to the incubation with palmitic
acid only, instead of the more complex diabetic milieu.
TO901317 (TO) and GW3965 (GW) Induce Scd-1 and
Scd-2 and Ameliorate Palmitic AcideInduced Podocyte
Death
Previously, we reported that MUFAs protect podocytes from
palmitic acideinduced death.9 We found in this study that
human SCD-1, which shares high homology to murine Scd-1
and Scd-2,33 is up-regulated in podocytes of DN patients. To
determine the functional relevance of SCD expression in
podocytes, we tested the effect of SCD induction on palmitic
acideinduced podocyte death. We ﬁrst took advantage of
TO901317 (TO) and GW3965 (GW), both LXR agonists,
which are known Scd-1 inducers.19 Having conﬁrmed the
presence of LXRs in podocytes (Figure 2A), we examined the
effect of TO and GW on Scd mRNA expression. TO and GW
induced Scd-1 (31-  3-fold and 33-  11-fold, P < 0.01)737
Figure 1 Expression of fatty acid metabolism associated enzymes in human DN and cultured podocytes exposed to palmitic acid. A: Microarray data were
obtained from isolated glomeruli of type 2 diabetic patients with DN and controls (pretransplantion allograft biopsy specimens). Gene expressions of ACC-2,
CPT-1a, CPT-1b, CPT-1c, DGAT1, DGAT2, SCD-1, and SCD-5 were signiﬁcantly regulated in DN compared with controls with SCD-1 that had the highest up-
regulation. Up-regulated enzymes are indicated in red and down-regulated enzymes in blue. The related metabolic pathways of enzymes analyzed are
depicted in the bottom panels. B: Immunoperoxidase staining against SCD-1 in a tumor nephrectomy specimen from a middle-aged adult without any known
history of medical renal disease. No signiﬁcant expression of SCD-1 is seen in glomeruli. Mild, granular cytoplasmic staining of renal tubules is present.
Representative sample of four nephrectomies analyzed is shown. C: Murine podocytes treated with 200 mmol/L palmitic acid for 14 hours induced mRNA levels
of Scd-1, Scd-2, and Cpt-1a, whereas levels of Cpt-1b, Cpt-1c, Dgat1, Dgat2, AccI, and AccII remained unchanged. Bar graph represents fold induction  SD of
enzymes normalized to Gapdh. BSA control treatment was set to 1 (n Z 9; **P < 0.01, ***P < 0.001, ****P < 0.0001). D: Immunoperoxidase staining
against SCD-1 in a renal biopsy specimen from a 57-year-old man with type 2 diabetes mellitus revealing early DN and glomerular hypertrophy. Arrows point to
podocytes with intense, granular cytoplasmic staining for SCD-1. There is also some cytoplasmic staining of parietal cells. Representative example of four DN
samples analyzed. Scale bars: 20 mm (B and D).
Sieber et al(Figure 2A) and Scd-2 mRNA levels (19- 9-fold and 22-
8-fold, P < 0.01) (Figure 2A). In contrast, Scd-3 and Scd-4
mRNA levels were not increased by TO (data not shown).
The changes in mRNA expression were also accompanied by
changes in Scd-1 protein abundance (Figure 2B). Function-
ally, TO and GW prevented palmitic acideinduced podocyte
death assessed by ﬂow cytometry after staining for annexin V
and propidium iodide to a comparable degree (Figure 2C).
Speciﬁcally, apoptosis was inhibited by 40% to 60% and
necrosis by 20% to 30%. To conﬁrm the protective effect of
TO and GW with a second, independent approach, we
examined the activation of effector caspase 3 by Western
immunoblotting. Consistent with the annexin V/propidium
iodide data (Figure 2C), caspase 3 was less activated in the
presence of TO and GW (Supplemental Figure S2). For the
reason of the equivalent effects observed by TO and GW, all
further experiments were performed with TO only. Because
CHOP gene silencing attenuates palmitic acideinduced
podocyte death andMUFAs can prevent CHOPup-regulation,9
we next tested whether TO can also attenuate CHOP induction.738TO signiﬁcantly reducedCHOP induction by almost 50% (nZ
3; P < 0.05) (Figure 2D), which may explain, at least in part,
the prosurvival effect of TO.
Combined Gene Silencing of Scd-1 and Scd-2
Abrogates the Protective Effect of TO on Palmitic
AcideInduced Podocyte Death
To investigate the role of desaturases in the protective action
of TO, we ﬁrst generated Scd-1 knockdown podocytes by
lentiviral knockdown of Scd-1. A scrambled shRNA served
as a control. By real-time PCR, we found suppression of
Scd-1 expression (Figure 3A). Scd-1 silenced podocytes had
comparable overall apoptosis and necrosis (Figure 3B).
However, as indicated in Figure 3C, the effect of TO on
palmitic acideinduced apoptosis was reduced in Scd-
1edeﬁcient cells (34%  2%) compared with controls
(56%  5%, P < 0.01). Similar ﬁndings were observed for
apoptosis and necrosis combined (Figure 3E), but no
difference was detected for necrosis (Figure 3D). Becauseajp.amjpathol.org - The American Journal of Pathology
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also generated podocytes deﬁcient in Scd-2. Knockdown of
Scd-2 was comparable to Scd-1 (Figure 3A). Overall
apoptosis and necrosis tended to be slightly increased in
Scd-2edeﬁcient podocytes (Supplemental Figure S3A). In
contrast to Scd-1 knockdown podocytes (Figure 3, BeE),
the protective effect of TO was preserved in Scd-2e
deﬁcient podocytes (Supplemental Figure S3, AeD). Next,
we generated Scd-1/Scd-2 double-deﬁcient podocytes that
were highly susceptible to palmitic acideinduced cell death.The American Journal of Pathology - ajp.amjpathol.orgPalmitic acideinduced apoptosis increased from 8.5% 
1.0% in control cells to 21.6%  0.9% in Scd-1/Scd-2
double-deﬁcient cells (Figure 3F). Moreover, the protec-
tive effect of TO was almost completely lost in the Scd-1/
Scd-2 double-deﬁcient cells (Figure 3F). The protective
effect of TO on apoptosis was reduced from 40.3%  4.0%
in control cells to 11.1%  7.7% (P < 0.01) in Scd-1/Scd-2
double-silenced cells (Figure 3G). Similarly, the protective
effect of TO on apoptosis and necrosis combined was
reduced from 30.6%  1.1% in controls to 11.6%  7.9%
(P < 0.05) in Scd-1/Scd-2 double-silenced cells (Figure 3I),
whereas the TO effect was not signiﬁcantly different for
necrosis (Figure 3H). Together, these data indicate that
Scd-1 and Scd-2 induction is responsible for the protective
effect of TO. Furthermore, Scd-1 and Scd-2 are presumably
compensating for each other because single knockdown of
Scd-1 (Figure 3, BeE) had only a limited effect on the
protective effect of TO and single knockdown of Scd-2 did
even not affect the protective effect of TO (Supplemental
Figure S3, AeD).
Overexpression of Scd-1 Reduces Palmitic
AcideInduced Podocyte Apoptosis
To further explore the beneﬁcial role of desaturases on
palmitic acideinduced apoptosis in podocytes, we overex-
pressed Scd-1. Overexpression of Scd-1 was conﬁrmed by
Western immunoblotting (Figure 4A). Scd-1 overexpression
signiﬁcantly reduced palmitic acideinduced apoptosis
(7.0%  0.3% versus 10.3%  0.7%, P < 0.01) and
necrosis (5.7%  0.4% versus 7.3%  0.5%, P < 0.05)
(Figure 4B). The protective effect of Scd-1 overexpression
is consistent with the Scd-1e and Scd-2edependent
protective effect of TO (Figure 3, FeI).
MUFAs and TO Shift Palmitic Acid into TGs, and MUFAs
Induce Fatty Acid b-Oxidation
To examine changes in lipid storage and fatty acid oxidation
induced by MUFAs (oleic acid) and TO, we used tritium-
labeled palmitic acid to trace the incorporation of palmiticFigure 2 TO and GW strongly induce Scd-1 and Scd-2 and ameliorate
palmitic acideinduced cell death. A: Quantitative real-time PCR analysis of
Scd-1, Scd-2, Lxra, and Lxrb after 14 hours of 1 mmol/L TO or GW treat-
ment. Bar graph represents fold inductions  SD of each gene normalized
to Gapdh. Vehicle (dimethyl sulfoxide) treatment was set to 1 (nZ 3; **P
< 0.01). B: Western blot analysis of SCD-1 after 14 hours of treatment with
TO. GAPDH was used as a control. Bar graph represents relative expression
 SD of SCD-1. Vehicle (dimethyl sulfoxide) treatment was set to 100%
(n Z 4; **P < 0.01). C: 14 hours pretreatment with TO or GW attenuated
palmitic acideinduced podocyte death. Bar graph represents means  SD
percentages of apoptotic and necrotic cells (n Z 3; *P < 0.05, **P <
0.01). D: TO attenuated the palmitic acidemediated induction of CHOP.
Podocytes were pretreated with 1 mmol/L TO or vehicle (dimethyl sulfoxide)
for 14 hours and subsequently incubated with 200 mmol/L palmitic acid for
24 hours. CHOP levels were analyzed by Western blot. b-Actin served as
a loading control. Bar graph represents the relative means  SD expres-
sions (n Z 3; *P < 0.05). Vehicle treated controls were set to 100%.
739
Figure 3 Scd-1 single knockdown only partially prevents the protective effect of TO on palmitic acideinduced podocyte death, whereas combined silencing
of Scd-1 and Scd-2 completely abrogates the TO effect. A: Knockdown of Scd-1 and/or Scd-2 by shRNA suppresses the TO-mediated up-regulation of Scd-1 and
Scd-2. Bar graph indicates means  SD quantitative real-time PCR mRNA levels of Scd-1 and Scd-2 normalized to Gapdh [control (scrambled) levels were set
to 1; *P < 0.05, ***P < 0.001]. BeI: Scd-1 single- and Scd-1/Scd-2 double-silenced podocytes were pretreated with 1 mmol/L TO for 14 hours before addition
of 200 mmol/L palmitic acid for 48 hours. B and F: Means  SD percentages of apoptotic and necrotic cells (nZ 3; *P < 0.05, **P < 0.01). CeE and GeI:
Relative means  SD percent changes of apoptotic (C and G), necrotic (D and H), and apoptotic and necrotic cells (E and I). Vehicle-treated (dimethyl
sulfoxide) controls are set to 100% (n Z 3; *P < 0.05, **P < 0.01).
Sieber et alacidederived FFAs into DAGs and TGs and to estimate
levels of b-oxidation of palmitic acid. Analysis of the TG to
DAG ratio revealed a shift of palmitic acid toward TGs in
the presence of oleic acid and TO. Coincubation with oleic
acid strongly shifted the ratio toward the TG fraction (2.8- 
0.6-fold, P < 0.001) (Figure 5A). TO also increased the
proportion of fatty acids derived from tritium-labeled pal-
mitic acid incorporated in TGs in relation to DAGs but to
a lower extent (1.3-  0.2-fold, P < 0.001) (Figure 5B).
Looking at the single fractions, the presence of oleic acid
signiﬁcantly increased the radioactive-labeled TG fraction
(Figure 5C) but even more prominently reduced the radio-
activity in the DAG fraction (0.5-  0.1-fold of control
cells, P < 0.01) (Figure 5D), whereas TO had no signiﬁcant
effect on incorporation in DAGs (Figure 5D) but mainly
effected the incorporation in TGs (Figure 5C). We did not
measure [3H]-palmitic acid integrated into ceramides
because fumonisin B1, a ceramide synthetase inhibitor, had
no protection from palmitic acideinduced lipotoxicity in
podocytes (Supplemental Figure S4). Finally, we investi-
gated the effect of oleic acid and TO on palmitic acid
b-oxidation. Podocytes were incubated with 200 mmol/L
palmitic acid along with 0.5 mCi/mL of tritiated palmitic
acid. The formation of [3H2O] is used as a read out of
palmitic acid b-oxidation, and oxidation of palmitic acid is740expressed as disintegrations per minute normalized to the
total protein of cell lysates. Five hours of co-treatment with
oleic acid elevated b-oxidation by 30% to 40% (P < 0.001)
when compared with palmitic acidetreated podocytes
(Figure 6). In contrast, the presence of TO revealed no de-
tectable change in palmitic acid b-oxidation (Figure 6).
Discussion
Type 2 diabetes is characterized by dyslipidemia and
elevated FFAs,7 and podocytes are highly susceptible to
saturated FFAs but not MUFAs.9 We found that in the
glomeruli of type 2 diabetic patients with DN mRNA
expression levels of several key enzymes involved in fatty
acid metabolism are altered. The most prominent change is
the up-regulation of SCD-1, which results mainly from
increased expression in podocytes. Functionally, the LXR
agonists TO and GW protect podocytes against palmitic
acideinduced cell death in an Scd-1e and Scd-2e
dependent fashion. Moreover, oleic acid or TO promotes the
incorporation of palmitic acid into TGs, suggesting that the
protective effect of TO results at least in part from
compartmentalization of palmitic acid in safe lipid pools.10
The microarray data revealing increased expression of all
three CTP-1 isoforms and decreased expression of ACC-2ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Overexpressing SCD-1 partially protects from palmitic acide
induced apoptosis. A: Western blot analysis of SCD-1 levels in green ﬂuo-
rescent protein or SCD-1 overexpressing podocytes. b-Actin served as
a loading control. B: SCD-1 reduced palmitic acideinduced apoptosis and
necrosis in podocytes. Bar graph represents means  SD percentages of
apoptotic and necrotic cells after exposure to 200 mmol/L palmitic acid for
48 hours (nZ 3; *P < 0.05, **P < 0.01; representative experiment of ﬁve
independent experiments).
Figure 5 Oleic acid and TO) increase palmitic acid incorporation into the
triglycerides (TG) fraction but only oleic acid reduces palmitic acid con-
taining DAG levels in palmitic acidetreated podocytes. Podocytes were
incubated for 5 hours in serum-free medium containing 0.5% FFA-free BSA
and supplemented with 200 mmol/L palmitic acid (1 mmol/L TO) or oleic
and palmitic acid (100 mmol/L each) in the presence of 0.5mCi/mL of [3H]-
palmitic acid. TG and DAG fractions were separated by thin layer chroma-
tography and analyzed by a liquid scintillation counter. A and B: Bar graphs
represent the means  SD ratios of [3H]-palmitic acid incorporated into TG
versus DAG (nZ 9; ***P< 0.001). C and D: Bar graphs represent the means
 SD incorporation of [3H]-palmitic acid into TG (C) and DAG (D) normalized
to total lipids (nZ 9; **P < 0.01). Vehicle treatment was set to 1.
***
Figure 6 Co-treatment with oleic acid but not TO increases palmitic
acid b-oxidation. Podocytes were incubated for 5 hours in serum-free
medium containing 0.5% FFA-free BSA and supplemented with 200
mmol/L palmitic acid (1 mmol/L TO) or oleic and palmitic acid (100 mmol/L
each) in the presence of 0.5 mCi/mL of [3H]-palmitic acid. b-Oxidation was
determined by counting [3H2O] as a product of b-oxidation in the aqueous
phase of the incubation medium. Bar graph represents means  SD
b-oxidation (nZ 9; ***P < 0.001). Vehicle treatment was set to 100%.
SCD-1 and -2 Protect Podocytessuggest an increased capacity for FFA oxidation. This ﬁnding
is particularly relevant because increased fatty acid oxidation
may protect against DN. Consistently, two recent genome-
wide association studies in type 2 diabetic patients found
a polymorphism in a noncoding region of ACC-2, with
a strong association with proteinuria.34,35 Importantly, the
DN-risk single-nucleotide polymorphism of ACC-2 results
in a higher ACC-2 expression,34 which favors impairment of
fatty acid oxidation. On the basis of these results, the higher
expression levels of all CPT-1 isoforms and the lower ACC-2
expression observed in the present study may be part of
a protective response against lipotoxicity.
The most prominent change in the microarray analysis
was the up-regulation of glomerular SCD-1, which could be
conﬁrmed in four independent patients at the protein level.
Of note, on renal biopsy specimens, SCD-1 expression was
mainly observed in podocytes. In contrast, a previous study
in mice found a reduction of Scd-1 expression in mice.36
However, the results of this murine study were obtained
from whole kidney extracts in a model of type 1 diabetes.
Thus, the changes in the type 1 model may come from
a different compartment but not from glomeruli, as done in
the present study.
Several lines of evidence indicate a protective role of
SCDs against saturated FFAs, such as palmitic acid.
Speciﬁcally, the LXR agonists TO and GW, which increase
levels of desaturases, also reduce palmitic acideinduced cell
death. Similarly, overexpression of Scd-1 attenuates pal-
mitic acideinduced cell death. Moreover, the protective
effect of TO was lost after gene silencing of Scd-1/-2,The American Journal of Pathology - ajp.amjpathol.orgthereby further conﬁrming that the protective effect of TO is
mediated by Scd-1/-2. Although we cannot rule out that the
protective effect of TO or GW involves other targets,
including other enzymes involved in FFA metabolism,37 the
loss of TO-mediated protection in Scd-1/-2 double-deﬁcient
podocytes, suggests a major role of SCDs.
The mechanisms whereby MUFAs protect against satu-
rated FFAs are incompletely understood. MUFAs, such as
oleic acid, can increase fatty acid incorporation into TGs
and increase fatty acid oxidation, thereby reducing biolog-
ically active saturated FFAs and avoiding the formation of741
Figure 7 A working model for the prosurvival effects TO/GW-induced
Scd-1/2 and oleic acid on palmitic acideinduced podocyte death. Pal-
mitic acid increases the generation of toxic metabolites, which leads to ER
stress and podocyte death. TO and GW increase Scd-1/2 expression, which
in turn elevates the TG safe pool and reduces injurious metabolites and
subsequent podocyte death. Similarly, oleic acid ameliorates palmitic
acideinduced podocyte death by shifting palmitic acid and toxic metab-
olites to the TG safe pool. In addition, oleic acid but not TO/GW also
increases b-oxidation.
Sieber et alcytotoxic metabolites, such as DAGs and ceramides.10 We
found that TO favors palmitic acidederived FFA incorpo-
ration into TG. The effect was even more pronounced in
podocytes co-incubated with oleic acid. TO has no signiﬁ-
cant effect on palmitic acidederived FFA incorporated
into DAGs. Previously, it has been suggested that DAG-
mediated lipotoxicity may depend on the saturation of
fatty acids incorporated in DAGs.38 Thus, the beneﬁcial
action of TO on palmitic acideinduced podocyte death may
still be in part due to an increase in palmitic acidederived
MUFAs incorporated in DAGs. In addition, the increased
amount of palmitic acid recovered from TGs after treatment
with TO is likely protective because palmitic acid is stored
away in a safe lipid pool.10 It is also worth mentioning that
oleic acid but not TO increased palmitic acid b-oxidation.
These differences in the synthesis of TGs and the up-
regulation of b-oxidation after oleic acid versus TO treat-
ment may account for the more protective effect of oleic
acid.
MUFAs can prevent the up-regulation of CHOP, which
likely contributes further to their protective effect because
gene silencing of CHOP attenuates palmitic acideinduced
cell death.9 Interestingly, TO also signiﬁcantly reduces the
induction of CHOP in podocytes exposed to palmitic acid,
which may result from the TO-induced increase in Scd-1/-2,
thereby promoting a shift from saturated FFAs as palmitic
acid to MUFAs. Clearly, more experiments are needed to
clarify this interesting observation.
A limitation of our study is that the relevance of CHOP
and the regulation of podocyte cell death by saturated FFAs
and MUFAs in kidneys of patients with DN require further
exploration. By immunohistochemistry no obvious CHOP
induction was seen in glomeruli of DN patients (unpub-
lished observation). Although podocyte loss or death clearly
contributed to the progression of DN,4,5 we did not observe
apoptosis in our patient biopsy specimens. Both the absence
of CHOP staining and apoptosis detection may be due to the
slow progression of DN, which makes it challenging to
capture these events. Future studies are needed to conﬁrm or
refute this hypothesis.
The role of SCDs and increased TG content in the devel-
opment of type2 diabetes is under debate.39 Scd-1 deﬁciency in
mice attenuates high fat dieteinduced obesity and insulin
resistance40 but at the same time promotes inﬂammation and
atherosclerosis.41 The favorable effect of Scd-1 deﬁciency on
diet-induced obesity is associated with altered skin lipid
composition, leading to decreased skin insulation and
a substantial increase in energy expenditure,whichmay at least
in part explain the increased insulin sensitivity in this model.42
The role of TG storage in nonadipose tissue may be context
dependent. Insulin-resistant obese rodents have increased
intramuscular TG content and synthesis rates.43 In contrast, in
humans the so-called athletes paradox indicates that ectopic fat
accumulation in muscles per se is not negative because
endurance-trained humans have higher insulin sensitivity and
increased intramuscular TG stores.44 Furthermore, transgenic742mice overexpressing the TG-synthesizing enzyme DGAT1 in
the heart have increased TG content and improved cardiac
function.45
In conclusion, our results suggest that the glomerular
SCD-1 up-regulation in DN may be part of a protective
mechanism against saturated FFAs. The following working
model can be suggested based on our functional studies for
the prosurvival effects of Scd-1 and/or Scd-2 and oleic acid
on podocytes (Figure 7). Palmitic acid increases the gener-
ation of toxic metabolites, which leads to ER stress and
podocyte death.9 Induction of Scd-1/-2 expression by TO or
GW elevates the TG safe pool, which in turn reduces
injurious metabolites and prevents podocyte death. Simi-
larly, oleic acid mitigates palmitic acideinduced podocyte
death by shifting palmitic acid and toxic metabolites to the
TG safe pool. In addition, oleic acid but not TO or GW
increase b-oxidation as an additional protective mechanism.
Our ﬁndings have potential therapeutic implications because
shifting of the FFA balance toward MUFAs and/or activa-
tion of SCD-1 in podocytes may help to prevent DN in type
2 diabetic patients.
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